Immunic Stock Performance

IMUX -  USA Stock  

USD 8.61  0.25  2.99%

The company retains a Market Volatility (i.e., Beta) of 1.0793, which attests to a somewhat significant risk relative to the market. Let's try to break down what Immunic's beta means in this case. Immunic returns are very sensitive to returns on the market. As the market goes up or down, Immunic is expected to follow. Although it is extremely important to respect Immunic current price history, it is better to be realistic regarding the information on equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By evaluating Immunic technical indicators, you can presently evaluate if the expected return of 0.0443% will be sustainable into the future. Immunic right now retains a risk of 4.01%. Please check out Immunic maximum drawdown, as well as the relationship between the skewness and day typical price to decide if Immunic will be following its current trending patterns.

Immunic Stock Performance 

 Immunic Performance
0 of 100
Over the last 90 days Immunic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Immunic is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more

Immunic Price Channel

Quick Ratio6.46
Fifty Two Week Low6.96
Target High Price71.00
Fifty Two Week High28.21
Target Low Price25.00

Immunic Relative Risk vs. Return Landscape

If you would invest  880.00  in Immunic on July 27, 2021 and sell it today you would lose (19.00)  from holding Immunic or give up 2.16% of portfolio value over 90 days. Immunic is currently generating 0.0443% in daily expected returns and assumes 4.011% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Immunic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Immunic is expected to generate 5.63 times more return on investment than the market. However, the company is 5.63 times more volatile than its market benchmark. It trades about 0.01 of its potential returns per unit of risk. The DOW is currently generating roughly 0.04 per unit of risk.

Immunic Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunic, and traders can use it to determine the average amount a Immunic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.011

Good Returns
Average Returns
Small Returns
Negative ReturnsIMUX
Estimated Market Risk
  actual daily
 34 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average Immunic is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunic by adding it to a well-diversified portfolio.

About Immunic Performance

To evaluate Immunic Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Immunic generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Immunic Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Immunic stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Immunic's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Effect of Exchange Rate Changes on Cash-78 K-84.2 K
Return on Average Assets(0.36) (0.39) 
Return on Average Equity(0.39) (0.42) 
Return on Invested Capital 50.15  42.88 
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.

Things to note about Immunic

Checking the ongoing alerts about Immunic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Immunic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Immunic Alerts

Equity Alerts and Improvement Suggestions

Immunic has very high historical volatility over the last 90 days
Immunic was previously known as Vital Therapies and was traded on NMS Exchange under the symbol VTL.
Net Loss for the year was (76.54 M) with loss before overhead, payroll, taxes, and interest of (4.91 K).
Immunic currently holds about 87.17 M in cash with (67.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.32.
Immunic has a very weak financial position based on the latest SEC disclosures
Roughly 25.0% of the company shares are held by company insiders
Latest headline from Immunic gains 3.34 percent on Moderate Volume October 15 -
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.